Musk testimony dominated first week of Musk v. Altman trial showdown

Elon Musk took the stand in the high‑profile Musk v. Altman trial in Oakland, framing his lawsuit as a defense of OpenAI’s original nonprofit mission and repeatedly telling jurors that “it’s not OK to steal a charity.” His testimony became the focal point of the first week of proceedings.

Over more than seven hours across three days on the witness stand, Musk recounted his role in founding OpenAI, his early financial contributions and his concerns about the organization’s pivot toward commercialization. The complaint seeks roughly $150 billion in damages and the unwinding of certain commercial arrangements, with proceeds intended for OpenAI’s charitable arm, according to court filings and reporting. Musk’s legal team argued the shift undermined the lab’s public‑interest mission.

Markets have taken notice: shares of companies closely tied to OpenAI’s ecosystem have experienced volatility as investors price in legal and strategic uncertainty. Commentators highlighted pressure on Microsoft (MSFT) given its deep commercial ties to OpenAI, while broader AI‑linked and infrastructure names have seen sentiment swings as the trial unfolded. Short‑term risk premia on AI exposure rose as traders reassessed potential impacts on partnerships and monetization.

Beyond immediate market moves, the case underscores a larger tension between mission‑driven governance and profit motives in fast‑moving tech sectors. If a court were to order structural remedies or disgorgement, the effects could reach licensing deals, revenue shares and the timeline for any potential OpenAI public offering. Regulators, boards and investors will watch the legal process for precedents affecting governance of well‑capitalized research labs.

Analysts differ on likely outcomes: some warn of a prolonged legal overhang that could delay strategic plans and weigh on partner valuations, while others see limited long‑term fallout absent a dramatic remedy. Legal experts note that even a verdict for Musk could result in lengthy equitable remedies and appeals, meaning market participants should expect sustained uncertainty in AI‑linked equities for months. The trial’s next phases and testimony from other industry figures will be closely monitored for signals about both legal liability and commercial exposure.